Rese-cel Shows Biologic Activity, No Preconditioning Needed
In three evaluable patients with pemphigus vulgaris (PV) treated with rese-cel at 1 x 10^6 cells/kg without preconditioning, Cabaletta...
New Study Advances Independence for People with Vision Loss
Two of three augmented-reality headsets evaluated in a peer-reviewed study of people with low vision delivered measurable gains in...
Positive Phase 2 Data for Alterity’s Parkinson’s Drug ATH434
ATH434 reduced disease progression on the modified UMSARS Part I at 52 weeks with a 48% relative treatment effect...
Pharma Unveils B-FREE Trial for Chronic Babesiosis Study
Phase 2 open-label study in chronic babesiosis will test a 90-day tafenoquine regimen with a primary patient-reported fatigue endpoint...
Onco3R Completes Phase 1 First Cohort for SIK3 Inhibitor
Phase 1 topline: Onco3R Therapeutics completed dosing of the first cohort (n=6) in its first-in-human study of O3R-5671 with...
Dye-Driven Precision: Targeting Chemo Directly to Tumors
Lyle Small leads a biotech startup pursuing a bold new approach: dye-drug conjugates that carry chemotherapy directly to cancer...
Functional Improvement Seen in Dyne’s One-Year DM1 Trial Data
One-year data from six adults with myotonic dystrophy type 1 (DM1) treated with zeleciment basivarsen at 6.8 mg/kg every...
Rheumatologists’ Powerful Hope: Cell Therapy for Sclerosis
Survey data from 104 US rheumatologists point to guarded enthusiasm for cell therapy in autoimmune disease: most hold favorable...
Nilo Therapeutics Launches with $101M to Target Immune Disease
Nilo Therapeutics launched with a $101 million Series A led by The Column Group, DCVC Bio, and Lux Capital,...
Pioneering Orphan Drug Updates from Sharp Therapeutics in 2025
No human data were disclosed. Sharp Therapeutics plans to present a Phase 1–ready preclinical package for its small‑molecule candidate...